Discover what Emgality can do for patients with chronic migraine1
For your patients with ≥15 headache days per month,1

Having chronic migraine means that at least half my month will be headache days. I need a preventive treatment so I can try to be with my family as much as possible.
— Hypothetical patient with chronic migraine
Review safety profile or the results from the 12-month, open-label safety study for Emgality
References:
- Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0002.
- Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0120.
- Bagley, CL, Rendas-Baum R, Maglinte GA, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52:409-421.